Characterization of Clinical Features and Survival of Patients with Autoimmune-Associated Diffuse Large B Cell Lymphoma in a Large Institutional Cohort

Conclusions: In this retrospective study of over 1,000 patients with DLBCL, concomitant AI disease was uncommon. A more complete evaluation of factors impacting survival in AI-associated DLBCL was limited by small sample size and incomplete documentation of key lymphoma and AI disease features in this dataset. The possibility of lower OS for patients with SLE and other AI diseases should be explored in future prospective studies, which may also better capture molecular features of both DLBCL and AI disease.DisclosuresFlowers: Pharmacyclics/ Janssen: Consultancy; Gilead: Consultancy; Gilead: Research Funding; Abbvie: Research Funding; Burroughs Wellcome Fund: Research Funding; Janssen Pharmaceutical: Research Funding; Genentech/Roche: Research Funding; Spectrum: Consultancy; V Foundation: Research Funding; Pharmacyclics: Research Funding; TG Therapeutics: Research Funding; OptumRx: Consultancy; Eastern Cooperative Oncology Group: Research Funding; Karyopharm: Consultancy; Genentech/Roche: Consultancy; National Cancer Institute: Research Funding; Denovo Biopharma: Consultancy; Millennium/Takeda: Research Funding; Bayer: Consultancy; Abbvie: Consultancy, Research Funding; Celgene: Research Funding; BeiGene: Research Funding; Acerta: Research Funding.

Source: Blood - November 21, 2018 Category: Hematology Authors: Barr, A. C., Goyal, S., Flowers, C. R., Koff, J. L. Tags: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)-Results from Retrospective/Observational Studies: Poster III Source Type: research